Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening

Gu, Dongyan; Cheng, Gang; Zhang, Mengmeng; Zhou, Yubo; Li, Jia; Sheng, Rong

doi:10.1016/j.bmc.2020.115863

Cited by 7 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gu et al. synthesised 2–(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl) derivatives 56a and 56b ( Figure 4 ), and evaluated their inhibitory activity against PI3Kα in vitro , with IC 50 values of 6.6 ± 2.1 and 7.6 ± 4.2 μM, respectively 60 .…”

Section: Oxadiazolementioning

confidence: 99%

Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review

Wang

Sun

Jia

et al. 2022

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Oxadiazole is a five-membered heterocyclic compound containing two nitrogen atoms and one oxygen atom. The 1,3,4-oxadiazole and 1,2,4-oxadiazole have favourable physical, chemical, and pharmacokinetic properties, which significantly increase their pharmacological activity via hydrogen bond interactions with biomacromolecules. In recent years, oxadiazole has been demonstrated to be the biologically active unit in a number of compounds. Oxadiazole derivatives exhibit antibacterial, anti-inflammatory, anti-tuberculous, anti-fungal, anti-diabetic and anticancer activities. In this paper, we report a series of compounds containing oxadiazole rings that have been published in the last three years only (2020–2022) as there was no report or their activities described in any article in 2019, which will be useful to scientists in research fields of organic synthesis, medicinal chemistry, and pharmacology.

show abstract

Section: Oxadiazolementioning

confidence: 99%

Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review

Wang

Sun

Jia

et al. 2022

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…In silico strategies have been reported for seeking novel compounds from chemical libraries (Reddy et al, 2007;Riva et al, 2019;Sabe et al, 2021). Conformation-based interactions of small molecule targets have been developed as a computational perspective for virtual drug screening (Divya & Pushpa, 2021;Gu et al, 2021;Y. Wang et al, 2020;Zhang et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies

et al. 2021

View full text Add to dashboard Cite

Epidermal growth factor receptor tyrosine kinase domain (EGFR-TK) has been one of the prominent targets for therapeutics of several human cancers, in particular non-small cell lung cancer. Although several small chemical compounds targeting EGFR-TK have been approved by FDA for treatment of such a cancer, the discovery of a new class of EGFR-TK inhibitors, for example, small peptides, is still desired. In this study, using molecular docking-based virtual screening, we selected five small peptides with high docking scores from eight thousand peptides as candidate compounds against EGFR-TK. Among five, the tripeptide WFF had the most potency to suppress the survival of non-small cell lung cancer cells but had the least toxicity to human liver cancer cells. Our in vitro kinase assays showed that WFF exhibited much lower inhibitory activity against purified EGFR-TK than the drug erlotinib (i.e., IC 50 values of ≈ 0.62 μM vs ≈ 7.57 nM, respectively). The relative free binding energies estimated from molecular dynamic simulations were consistent with the in vitro experiments in which the WFF bound had a lower affinity than erlotinib bound to EGFR-TK (i.e., ΔG bind values of −20.3 kJ/mol vs ≈ −126.8 kJ/mol, respectively). In addition, the simulation analyses demonstrated the difference in EGFR binding preference between the drug and tripeptide in which erlotinib was stably bound in the ATP-binding pocket for 4-anilinoquinazoline class of inhibitors, while WFF moved out of that pocket to interact with polar amino acid residues on the αC-helix, activation loop,

show abstract

Photophysical and Docking Studies of Schiff Base Coupled Silane: A Probe for Sn²⁺ Detection and PI3Kα Inhibitor for Cancer Treatment

Singh,

Tamana,

Khurana

et al. 2024

Applied Organom Chemis

View full text Add to dashboard Cite

Cancer, a leading cause of death globally, necessitates clinical research to develop effective solutions to reduce mortality rates. Currently, scientists are focusing on two prominent topics in cancer treatment: the presence of Sn2+ in cells and the inhibition of the phosphoinositide 3‐kinase enzyme (PI3Kα). In this study, Schiff base‐coupled silane 7a {C26H35N5O6Si (M + H+ = 540.53)} has been synthesized that could detect Sn2+, which in trace amounts can help prevent cancer, and it also inhibits PI3Kα enzyme, thereby preventing the rapid proliferation of cancer cells. The detection limit and binding constant calculated via Fluorescence studies were found to be 3.46 × 10−8 M and 9.4 × 104 M−1, respectively. The value of inhibition constant of silane for PI3Kα enzyme was also found to be 2.52 nM via molecular docking.

show abstract

Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening

Cited by 7 publications

References 35 publications

Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review

Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review

Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies

Photophysical and Docking Studies of Schiff Base Coupled Silane: A Probe for Sn²⁺ Detection and PI3Kα Inhibitor for Cancer Treatment

Contact Info

Product

Resources

About

Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening

Cited by 7 publications

References 35 publications

Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review

Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review

Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies

Photophysical and Docking Studies of Schiff Base Coupled Silane: A Probe for Sn2+ Detection and PI3Kα Inhibitor for Cancer Treatment

Contact Info

Product

Resources

About

Photophysical and Docking Studies of Schiff Base Coupled Silane: A Probe for Sn²⁺ Detection and PI3Kα Inhibitor for Cancer Treatment